SYRE
SYRE
US00773J2024
Spyre Therapeutics, Inc.
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue -- --
--
Cost of Revenue -- --
--
Gross Profit -- --
--
219.562.000 208.566.000
5.3%
Operating Income -219.562.000 -208.566.000
5.3%
Pretax Income -155.218.000 -207.967.000
25.4%
Net Income Common Stockholders -155.203.000 -208.018.000
25.4%
-- --
--
-- --
--
ende